EGLT News Alert Egalet Corp (EGLT) 5.97 12/25/2014 00:58:07

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Egalet Corp (EGLT) 5.97 $EGLT

Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
EGLT: 5.97 (+0.21), LNCO: 10.87 (-0.44), ASPS: 33.81 (+4.37), DERM: 19.65 (+0.38), MCEP: 6.07 (-0.12), GTIM: 6.13 (-0.07), LINE: 10.93 (-0.32), ORPN: 6.25 (-0.35), NYNY: 7.89 (+0.32), POZN: 7.86 (+0.07), OTIC: 32.26 (+0.65)

Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 12.65 (+0.66), ACRX: 6.61 (+0.06), EGLT: 5.97 (+0.21), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities 2014-19: Egalet 002 to Take Over from Oxycontin and Oxycodone
M2 - Mon Dec 08, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/t568bs/the_us_chronic) has announced the addition of the "The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-19)" report to their offering. The report titled The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019) provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market. Company Coverage - Zogenix Inc. - Egalet Corporation - NektarTheropeutics Key Topics Covered: 1. Executive summary 2. Introduction: Chronic Pain 3. The US Chronic Pain Therapy Market 4. The US Chronic Pain Therapy Market: Segment Analysis 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market 8. Competitive Landscape:The US Chronic Pain Therapy Market 9. Company Profiles:The US Chronic Pain Therapy Market For more information visit http://www.researchandmarkets.com/research/t5...us_chronic
EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04)

United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com
PRWeb - Tue Dec 02, 2:55AM CST
The report titled "The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)" provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.
EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04)

FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST

MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Egalet's (EGLT) CEO Bob Radie on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:18AM CST

EGLT: 5.97 (+0.21)

Egalet net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:29AM CST

EGLT: 5.97 (+0.21)

Egalet beats by $0.14
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:41AM CST

EGLT: 5.97 (+0.21)

Egalet Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Wed Nov 12, 5:00AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today reported business highlights and financial results for the three months ended September 30, 2014.
EGLT: 5.97 (+0.21)

Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 12.65 (+0.66), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), AXN: 0.31 (+0.01), SRNE: 9.50 (+0.99), NKTR: 15.02 (+0.23), EGLT: 5.97 (+0.21), AZN: 70.44 (+0.26), VBAY: ()

Egalet to Present at the Stifel 2014 Healthcare Conference on November 18
GlobeNewswire - Wed Nov 05, 7:30AM CST
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:10 p.m. EST. The conference will be held at the New York Palace Hotel.
EGLT: 5.97 (+0.21)

Egalet to Host Conference Call and Webcast to Discuss Third Quarter Financial Results on November 12, 2014
PR Newswire - Wed Oct 29, 7:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today announced that its third quarter financial results will be released on Wednesday, November 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update.
EGLT: 5.97 (+0.21)

FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT

MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

2 Oversold Stocks Under $10 Ready to Bounce Higher
at The Street - Fri Oct 17, 8:05AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can experience a powerful bounce higher.
AMKR: 7.16 (+0.21), EGLT: 5.97 (+0.21)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 41

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading

Top 5 Most Recently Viewed Articles

MSG Entertainment Reports Q1 Results for Fiscal 2025

Updated Category News Views 259

MSG Entertainment's Strong Start to Fiscal 2025 Madison Square Garden Entertainment Corp. (NYSE: MSGE) has released its financial results for the first quarter of fiscal 2025, providing insight into its performance and future expectations. The company, known for its impressive entertainment offerings, has experienced a robust period marked by several noteworthy...

Continue Reading
Asia Pacific Consumer Trends 2025: Emphasizing Intentional Spending

Updated Category News Views 1304

Embracing Intentional Spending in Asia Pacific NielsenIQ (NIQ), the foremost global consumer intelligence company, has published its Mid-Year Consumer Outlook (MYCO) report highlighting a significant transition among Asia Pacific consumers. This report underscores how consumers are moving away from cautious spending towards more intentional and purpose-driven consumption....

Continue Reading
BILL Holdings Sees Stock Surge as Investor Takes 8% Share

Updated Category News Views 303

Stock Rise for BILL Holdings Inc BILL Holdings Inc (NYSE: BILL) has experienced a noticeable surge in its stock price during after-hours trading recently. This uptick follows reports indicating that the activist investment firm Starboard Value has acquired an 8% stake in the company. Overview of the Recent Developments After hours, BILL stock showed signs of strength,...

Continue Reading
Saudi Fund for Development Fuels Growth in Serbia with $205M Deals

Updated Category News Views 84

Saudi Fund for Development Boosts Economic Growth in Serbia The Saudi Fund for Development (SFD) is making significant strides in fostering growth in Serbia through the signing of three major development loan agreements, totaling $205 million. This initiative marks the Fund's first venture into Serbia, reflecting its commitment to promoting sustainable development across...

Continue Reading
Chevron's 2025 Capex Budget and Strategic Update Overview

Updated Category News Views 487

Chevron's Strategic Vision for 2025 Capex Budget Chevron Corporation has announced its ambitious 2025 capital expenditure budget, setting the range between $14.5 to $15.5 billion for its consolidated subsidiaries, alongside an affiliate capex range of $1.7 to $2.0 billion. This capex approach emphasizes Chevron's commitment to operational excellence and enhanced...

Continue Reading